Discovery offers new treatment for epilepsy

New drugs derived from components of a specific diet used by children with severe, drug-resistant epilepsy could offer a new treatment, according to research published today in the journal Neuropharmacology.

Scientists from Royal Holloway, in collaboration with University College London, have identified specific fatty acids that have potent antiepileptic effects, which could help control seizures in children and adults.

The discovery could lead to the replacement of the ketogenic , which is often prescribed for children with severe drug-resistant epilepsy. The high fat, is thought to mimic aspects of starvation by forcing the body to burn fats rather than carbohydrates. Although often effective, the diet has attracted criticism, as side effects can be significant and potentially lead to constipation, hypoglycaemia, retarded growth and .

By pinpointing fatty acids in the ketogenic diet that are effective in controlling epilepsy, researchers hope that they can develop a pill for children and adults that could provide similar epilepsy control, but lacks the side effects of the diet.

Professor Robin Williams from the Centre of at Royal Holloway said: "This is an important breakthrough. The family of medium chain fatty acids that we have identified provide an exciting new field of research with the potential of identifying, stronger, and safer epilepsy treatments."

The study tested a range of fatty acids found in the against an established epilepsy treatment. Researchers found that not only did some of the fatty acids outperform the drug in controlling seizures, they also had fewer side effects.

Professor Matthew Walker from the Institute of Neurology, University College London said: "Epilepsy affects over 50 million people worldwide and approximately a third of these people have epilepsy that is not adequately controlled by our present treatments. This discovery offers a whole new approach to the treatment of drug-resistant epilepsies in children and adults."

The research also builds on work funded by the NC3Rs in which most of the animal testing normally used in drug development for epilepsy has been replaced by using a simple amoeba to initially screen and identify improved treatments.

Professor Williams added: "Animals are often used in the search for new treatments. Our work provides a new approach, helping us to reduce reliance on animals and provide potential major improvements in human health."

The specific identified in this work are the subject of a patent application, and Royal Holloway is seeking commercial collaborators to pursue the potential for new drug development.

Related Stories

Diet may eliminate spasms for infants with epilepsy

Sep 08, 2008

Infantile spasms are a severe and potentially devastating epilepsy condition affecting children aged typically 4-8 months. In a new study appearing in Epilepsia, researchers have found that the ketogenic diet, a high fat, l ...

Diabetes drug may hold potential as treatment for epilepsy

Apr 09, 2008

Metformine, a widely used diabetic drug, might also be an effective and safe therapy for epilepsy, researchers report. This new approach may be especially helpful for the subset of patients who have recurrent seizures despite ...

Recommended for you

What happens in our brain when we unlock a door?

52 minutes ago

People who are unable to button up their jacket or who find it difficult to insert a key in lock suffer from a condition known as apraxia. This means that their motor skills have been impaired – as a result ...

Sport can help multiple sclerosis patients

4 hours ago

A study developed at the Miguel Hernández University of Elche (Spain) has preliminarily concluded that people with multiple sclerosis may reduce perceived fatigue and increase mobility through a series of ...

Obama's BRAIN initiative gets more than $300 million

9 hours ago

President Barack Obama's initiative to study the brain and improve treatment of conditions like Alzheimer's and autism was given a boost Tuesday with the announcement of more than $300 million in funds.

User comments